Annika Kim Constantino is a Digital Reporter at CNBC. She covers the biotech and pharmaceutical industry, focusing on themes such as medicine and healthcare, public health, and pharmaceutical regulation. Annika's work has been featured in notable outlets including NBC News, Yahoo News, and NBC Bay Area.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Annika Kim Constantino's coverage primarily focuses on the healthcare and pharmaceutical industry within the United States. She frequently cites data, reports on government announcements, and incorporates press releases into her articles.
Given this focus, she may be receptive to pitches from experts in the healthcare and pharmaceutical industries who can provide analysis or commentary on drug approvals, vaccine development, health regulations, company news (especially those related to U.S.-based companies), patent challenges, or other relevant topics within the realm of healthcare and pharmaceuticals.
Pitches offering insights based on solid data or relating to recent government announcements in the U.S. healthcare sector would likely align well with Annika's coverage preferences.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Annika Kim Constantino
Makary's tenure was marked by internal dysfunction at the FDA, leadership turmoil and mounting backlash from drugmakers and physicians on regulatory decisions.
By: Annika Kim
Key Points A cruise ship outbreak of hantavirus has rattled the public and reignited fears of another global health scare, but health experts aim to tamp down fears of another pandemic.
CDC says there are no U.S. hantavirus cases currently, 41 people being monitored
By: Annika Kim Constantino
No cases tied to the Ebola outbreak have been confirmed in the U.S., and the overall risk to the American public and travelers remains low.
Trump said he is increasing the number of products on the platform by nearly seven times, adding more than 600 generic drugs to the site.
By: Annika Kim Constantino
The results bring Lilly one step closer to filing for approval of the injection, retatrutide, which works differently from existing injections and pills.
CVS will add Zepbound coverage on Oct. 1, and start covering Lilly's newly approved Foundayo pill on June 1. The move will boost Lilly's efforts to maintain its dominance over
The Trump administration is ramping up efforts to crack down on fraud in the federal Medicaid program.
The drugmaker announced it will buy three privately held vaccine makers in deals worth almost $4 billion combined.
CNBC's Annika Kim Constantino joins 'Squawk Box' with the latest news from Eli Lilly.
